Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• Z is CH, N, or
• Ring A is optionally substituted phenylene when Z is CH, optionally substituted pyridinylene when Z is N, or optionally substituted N-oxide pyridinylene when Z is
• Ar is optionally substituted 5 or 6-membered monocyclic arylene or heteroarylene, provided that when Ar is 5-membered heteroarylene, R2 and —C(O)NR3— are oriented 1, 3 to each other on the ring, wherein position 1 is the point of attachment of Ar to the —C(O)NR3—;
• or
• Ar is optionally substituted 9- or 10-membered fused bicyclic heteroarylene;
• R1 is —OR1A or —NR1AR1B;
• R1A, R1B are each independently hydrogen or C1-C4-alkyl;
• W is O, and L is —(CH2)n—, wherein n is an integer between 1 and 6, and one or more (CH2) is replaced with —CH2—CH(CH3)—, —CH(CH3)—CH2—, —CH2—C(CH3)2—, —C(CH3)2—CH2—, —HC═C(CH3)—, —(CH3)C═CH—,
• —CH2—O—CH2—, —CH2—S—CH2—, —CH2—CH(F)—, —CH(F)—CH2—, —CH2—CF2—, —CF2—CH2—, —CH2—C(O)—, —C(O)—CH2—, optionally substituted arylene, optionally substituted arylene ether, or optionally substituted heteroarylene;
• or
• W is CH2, CH═CH, or C≡C, and L is —(CH2)n—, wherein n is an integer between 1 and 6, and one or more (CH2) is optionally replaced with —CH2—CH(CH3)—, —CH(CH3)—CH2—, —CH2—C(CH3)2—, —C(CH3)2—CH2—, —HC═C(CH3)—, —(CH3)C═CH—,
• —CH2—O—CH2—, —CH2—S—CH2—, —CH2—CH(F)—, —CH(F)—CH2—, —CH2—CF2—, —CF2—CH2—, —CH2—C(O)—, or —C(O)—CH2—;
• each R21 is independently hydrogen, halogen, or C1-C4-alkyl;
• R2 is halogen, C1-C4-alkyl, C3-C6-cycloalkyl, CN, C1-C4-alkoxy, C1-C4-haloalkoxy, SO2(C1-C4-alkyl), 5- or 6-membered heterocycloalkyl, —≡—R2A, —O(CH2)mR2B, NH(C1-C4-alkyl), N(C1-C4-alkyl)2, C(O)(C1-C4-alkyl), optionally substituted aryl, or optionally substituted 5-membered heteroaryl;
• m is an integer having an a value of 0, 1, 2, or 3;
• R2A and R2B are each independently C1-C4-alkyl, C3-C6-cycloalkyl, or C1-C4 haloalkyl;
• R3 is C1-C4-alkyl,
• or C1-C4-haloalkyl;
• and
• each R4 is independently H, D, or F;
• with the proviso that the compound is not selected from the group consisting of:
• or a pharmaceutically acceptable salt thereof.